Inventor · disambiguated record
Murielle Veniant-Ellison
Also filed as: VENIANT ELLISON Murielle Marie · VENIANT-ELLISON MURIELLE · VENIANT-ELLISON MURIELLE M
13 granted patents·12 pending applications·191 citations·filing 2003–2025
92Inventor score
Top patents by PatentIndex Score
25 records- 0196US7229976B2Modulation of forkhead box O1A expressionISIS PHARMACEUTICALS INC·Filed 2003·Granted Jun 12, 2007·114 cites·35 claims
- 0292US9862752B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2014·Granted Jan 9, 2018·16 cites·27 claims
- 0392US9714276B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2013·Granted Jul 25, 2017·17 cites·18 claims
- 0491US10336798B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2017·Granted Jul 2, 2019·9 cites·21 claims
- 0591US10294303B2Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonistsAMGEN INC·Filed 2016·Granted May 21, 2019·12 cites·14 claims
- 0690US10905772B2Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)AMGEN INC·Filed 2018·Granted Feb 2, 2021·6 cites·18 claims
- 0790US10894814B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2017·Granted Jan 19, 2021·4 cites·25 claims
- 0886US12252540B2Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)AMGEN INC·Filed 2021·Granted Mar 18, 2025·1 cites·5 claims
- 0986US11046774B2Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonistsAMGEN INC·Filed 2019·Granted Jun 29, 2021·5 cites·18 claims
- 1084US11739131B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2019·Granted Aug 29, 2023·1 cites·6 claims
- 1184US2024368236A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2024·Application pending·0 cites
- 1282US7807649B2Modulation of forkhead box O1A expressionISIS PHARMACEUTICALS INC·Filed 2007·Granted Oct 5, 2010·4 cites·33 claims
- 1380US2025121056A1Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)AMGEN INC·Filed 2024·Application pending·0 cites
- 1478US2025319196A1Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteinsAMGEN INC·Filed 2025·Application pending·0 cites
- 1578US2024261421A1Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteinsAMGEN INC·Filed 2024·Application pending·0 cites
- 1671US2025376529A1Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonistsAMGEN INC·Filed 2025·Application pending·0 cites
- 1770US2021079051A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2020·Application pending·0 cites
- 1868US8288339B2GLP-1 compoundsGEGG JR COLIN VICTOR·Filed 2007·Granted Oct 16, 2012·2 cites·7 claims
- 1965US12465652B2Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteinsAMGEN INC·Filed 2018·Granted Nov 11, 2025·0 cites·20 claims
- 2059US2025277029A1Cannabinoid type 1 receptor binding proteins and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2149US2025276080A1Glucagon receptor agonists and conjugates to glucose-dependent insulinotropic polypeptide antagonistsAMGEN INC·Filed 2025·Application pending·0 cites
- 2241US2013203659A1Glp-1 compoundsMIRANDA LESLIE P·Filed 2012·Application pending·0 cites
- 2340US2006275285A1Methods of inhibiting a GPCRAMGEN INC·Filed 2006·Application pending·0 cites
- 2436US2017233467A1Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular TherapiesAMGEN INC·Filed 2015·Application pending·0 cites
- 2532US2018280474A1Treatment of bile acid disordersAMGEN INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →